1 completed, 1 withdrawn. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow DaTscan: new trials by email Literature Review of DaTscan trials Research Report on DaTscan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes NAV5001, DaTscan - Parkinson's Syndrome | Phase 3 | Withdrawn | Navidea Biopharmaceuticals | 2017-04-01 | 2017-09-13 | |
| Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia DatSCAN - Lewy Body Dementia, Non-DLB Dementia | Phase 3 | Completed | GE Healthcare | 326 | 2003-11-01 | 2007-05-16 |
Dementia, Vascular (1) · Lewy Body Disease (1) · Parkinson Disease (1)
GE Healthcare (1) · Navidea Biopharmaceuticals (1)
Germany (1) · United States (1)
Cornelia Reininger, M.D. Ph.D. (1) · Marc Pignot, PhD (1)